(Q41674270)

6 October 2017

1 reference

title

Terbinafine: an update (English)

1 reference

6 October 2017

0 references

1

1 reference

6 October 2017

N H Shear

2

1 reference

6 October 2017

language of work or name

English

0 references

publication date

1 December 1997

1 reference

Journal of the American Academy of Dermatology

6 October 2017

published in

1 reference

6 October 2017

volume

37

1 reference

6 October 2017

issue

6

1 reference

6 October 2017

page(s)

979-988

1 reference

Terbinafine: mode of action and properties of the squalene epoxidase inhibition

6 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Antifungal activity of the allylamine derivative terbinafine in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Dose-proportional pharmacokinetics of terbinafine and its N-demethylated metabolite in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Nail incorporation kinetics of terbinafine in onychomycosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Clinical pharmacokinetics of terbinafine (Lamisil).

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Treatment of chromomycosis with terbinafine: preliminary results of an open pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Overview of the use of terbinafine (Lamisil) in children.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Treatment of childhood dermatophyte infections with oral terbinafine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

An open clinical pilot study of the efficacy and safety of oral terbinafine in dry non-inflammatory tinea capitis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Pilot study of terbinafine in children suffering from tinea capitis: evaluation of efficacy, safety and pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

A randomized double-blind comparative study of terbinafine for 1, 2 and 4 weeks in tinea capitis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Therapeutic efficacy of terbinafine in the treatment of three children with tinea tonsurans

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Efficacy of terbinafine treatment of tinea capitis in children varies according to the dermatophyte species

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Human Trichophyton equinum infection treated with terbinafine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Onychomycosis in children: prevalence and treatment strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

The successful treatment of finger Trichophyton rubrum onychomycosis with oral terbinafine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Treatment of dermatophyte infection of the finger- and toe-nails with terbinafine (SF 86-327, Lamisil), an orally active fungicidal agent.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Short-duration therapy with terbinafine for dermatophyte onychomycosis: a multicentre trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

A randomized treatment duration-finding study of terbinafine in onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Treatment of onychomycosis with terbinafine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Short-duration treatment of fingernail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin. LAGOS III Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Onychomycosis treated with a short course of oral terbinafine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Open randomized comparison of itraconazole versus terbinafine in onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Treatment of onychomycosis with terbinafine in patients with Down's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Terbinafine in onychomycosis of the toenail: A novel treatment protocol

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

A 12-week treatment for dermatophyte toe onychomycosis: terbinafine 250 mg/day vs. itraconazole 200 mg/day--a double-blind comparative trial

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Meta-analysis for combining Bayesian probabilities

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Use of terbinafine in HIV-positive subjects: pilot studies in onychomycosis and oral candidiasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Single dose treatment of fungal nail disease

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Very short duration therapy with oral terbinafine for fingernail onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Intermittent therapy with terbinafine for dermatophyte toe-onychomycosis: a new approach

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Treatment of Candida nail infection with terbinafine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Systemic treatment of skin candidosis: a randomized comparison of terbinafine and ketoconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Terbinafine in onychomycosis with involvement by non-dermatophytic fungi

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Onychomycosis due to Scopulariopsis brevicaulis: clinical features and response to systemic antifungals.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Oral terbinafine versus griseofulvin in the treatment of moccasin-type tinea pedis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

A comparative study of terbinafine versus griseofulvin in 'dry-type' dermatophyte infections

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Successful treatment of chronic tinea pedis (moccasin type) with terbinafine (Lamisil).

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Successful 2-week treatment with terbinafine (Lamisil) for moccasin tinea pedis and tinea manuum

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Two-week oral treatment of tinea pedis, comparing terbinafine (250 mg/day) with itraconazole (100 mg/day): a double-blind, multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

A comparative double-blind study of terbinafine (Lamisil) and griseofulvin in tinea corporis and tinea cruris

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

One-week therapy with oral terbinafine in cases of tinea cruris/corporis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

A double-blind, randomized, stratified controlled study of the treatment of tinea imbricata with oral terbinafine or itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Terbinafine in the treatment of Majocchi's granuloma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Treatment of cutaneous sporotrichosis with terbinafine.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Black piedra: the first case treated with terbinafine (Lamisil).

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Management of drug therapy in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Hepatitis associated with terbinafine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Terbinafine-associated hepatic injury

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Hypersensitivity reaction to terbinafine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Oral terbinafine and erythema multiforme

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Toxic epidermal necrolysis induced by terbinafine in a patient on long-term anti-epileptics

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Terbinafine and erythema multiforme

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Stevens-Johnson syndrome after terbinafine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Terbinafine and fixed drug eruption

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Terbinafine therapy may be associated with the development of psoriasis de novo or its exacerbation: four case reports and a review of drug-induced psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Clinical singgnificance of interactions with antifungal agents

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Azoles, a48 llylamines and drug metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

The interaction of representative members from two classes of antimycotics--the azoles and the allylamines--with cytochromes P-450 in steroidogenic tissues and liver

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

A multinational pharmacoeconomic analysis of oral therapies for onychomycosis. The Onychomycosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Cost-effectiveness analysis for onychomycosis therapy in Canada from a government perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Clinical and economic factors in the treatment of onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2897%2970076-8

7 January 2021

10.1016/S0190-9622(97)70076-8

Identifiers

DOI

1 reference

6 October 2017

1 reference